Oncotarget

Research Papers:

Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity

Chunling Dong, Bo Li, Zhenyu Li, Sreerama Shetty and Jian Fu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:49699-49709. https://doi.org/10.18632/oncotarget.10435

Metrics: PDF 1562 views  |   HTML 2560 views  |   ?  


Abstract

Chunling Dong1,*, Bo Li2,*, Zhenyu Li3, Sreerama Shetty4, Jian Fu5,6

1Department of Respiratory Medicine, Second Hospital, Jilin University, Changchun, Jilin, P.R. China

2Department of Human Anatomy, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, P.R. China

3Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, Lexington, KY, USA

4Center for Biomedical Research, University of Texas Health Science Center at Tyler, Tyler, TX, USA

5Center for Research on Environmental Disease, College of Medicine, University of Kentucky, Lexington, KY, USA

6Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, KY, USA

*These authors contributed equally to this work

Correspondence to:

Jian Fu, email: jian.fu@uky.edu

Keywords: tyrosine kinase, endothelial barrier, leukemia, drug carrier, nanoparticles

Received: May 23, 2016     Accepted: June 26, 2016     Published: July 06, 2016

ABSTRACT

Dasatinib (DAS), a second-generation tyrosine kinase inhibitor, is highly effective in treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. However, its clinical use is limited due to serious adverse effects. DAS can disrupt endothelial barrier integrity and increase endothelial permeability which may cause peripheral edema and pleural effusion. Albumin nanoparticles (NPs) as a drug carrier may serve as a useful tool for cell-selective drug delivery to reduce DAS-induced endothelial hyperpermeability and maintain endothelial barrier integrity. In this study, we reported that DAS-loaded NPs exhibited potent anti-leukemia efficacy as DAS alone. Importantly, albumin NPs as a drug carrier markedly reduced DAS-induced endothelial hyperpermeability by restraining the inhibition of Lyn kinase signaling pathway in endothelial cells. Therefore, albumin NPs could be a potential tool to improve anti-leukemia efficacy of DAS through its cell-selective effects.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10435